Glycovir (SC-49483) is an ester produg (a biologically inactive compound that can be metabolized in the body to produce a drug) of SC 48334, an α-glycosidase 1 inhibitor that has anti-HIV activity. Glycovir was thus studied for treatment in HIV. It is targeted against viral glycoprotein processing in host cell endoplasmic reticulum. Bioavailability of the pharmacologically active SC-48334 observed after glycovir administration was found to be very different between species, but monkeys are a good animal model for prediction of bioavailability of SC-48334 in humans. A phase II trial was conducted to determine the safety and anti-HIV activity of a combination treatment of glycovir with zidovudine (AZT).